13
Feb
2017
Now More Than Ever: The Need for Personalized Medicine in Immuno-Oncology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
5
Jan
2017
Neon Therapeutics Gets $70M to Push Neoantigen Cancer Vaccines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
27
Sep
2016
Google Translate Star Leaves Venter’s Human Longevity to Join Illumina’s Grail
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
27
Jun
2016
The VP is Asking for Advice on Cancer. Share Yours Before I Go To Washington
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
19
May
2016
I-O: Who’s Doing What? (Part 2)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
16
May
2016
Immuno-Oncology: Who’s Doing What?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
10
Jan
2016
Illumina, Arch, Bezos, Gates Bet $100M on Deep Sequencing for Early Cancer Detection
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
8
Jan
2016
All the Biotech Deals and Financings You Can Grok Before JP Morgan 2016
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
21
Dec
2015
Which Biotechnologies Were Hyped, and Which Weren’t, in 2015
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
10
Nov
2015
Pursuing a Hard Cancer Target: Q&A With Warp Drive CEO Laurence Reid
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
2
Oct
2015
Fallout from the Drug Pricing Fiasco, the New Thing in Genome Editing & More
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
1
Oct
2015
The Next Macro (Phage) Thing in Immuno-Oncology
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
11
Sep
2015
Post-Labor Day Hangovers, Ipi-Nivo Combo Data & the PCSK9 Pricing Debate
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
19
Aug
2015
Not Just Research, Not Just Diagnostics: Adaptive Veers into T-Cell Drug Discovery
This content is available for subscribers of the Timmerman Report. Subscribe Now Sign in to your account.[/memberful_sign_in_link]
Share:
21
Jul
2015
The Non-Compete Chill Has Passed: Bristol-Myers, MedImmune Settle Over I-O Star
This content is available for subscribers of the Timmerman Report. Subscribe Now Sign in to your account.
Share:
17
Jul
2015
Forget Price Controls – Value-Based Pricing is the New Threat to Drug Development
This content is available for subscribers of the Timmerman Report. Subscribe Now Sign in to your account.
Share:
15
Jun
2015
It’s Time to Re-Think Some Assumptions About Cancer R&D
This content is available for subscribers of the Timmerman Report. Subscribe Now Sign in to your account.
Share:
11
Jun
2015
NEA, Polaris Bet $22M on Startup, Xtuit, to Break Down Tumor Microenvironment
This content is available for subscribers of the Timmerman Report. Subscribe Now Sign in to your account.
Share:
29
May
2015
Cancer Immunotherapy’s Amazing Four-Year Run: A Timeline of Events
This content is available for subscribers of the Timmerman Report. Subscribe Now Sign in to your account.
Share:
22
May
2015
The Genentech Alumni: Where Are They Now?
This content is available for subscribers of the Timmerman Report. Subscribe Now Sign in to your account.
Share: